CN105669682B - 一种dpp-iv抑制剂的中间体 - Google Patents

一种dpp-iv抑制剂的中间体 Download PDF

Info

Publication number
CN105669682B
CN105669682B CN201610101521.5A CN201610101521A CN105669682B CN 105669682 B CN105669682 B CN 105669682B CN 201610101521 A CN201610101521 A CN 201610101521A CN 105669682 B CN105669682 B CN 105669682B
Authority
CN
China
Prior art keywords
compound
product
reaction
obtains
reactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610101521.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105669682A (zh
Inventor
李进
斯托克斯·迈克尔
窦登峰
万金桥
冯静超
潘飞
宋宏梅
胡晓
易磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Pioneer Drug Development Co Ltd
Original Assignee
Chengdu Pioneer Drug Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Pioneer Drug Development Co Ltd filed Critical Chengdu Pioneer Drug Development Co Ltd
Publication of CN105669682A publication Critical patent/CN105669682A/zh
Application granted granted Critical
Publication of CN105669682B publication Critical patent/CN105669682B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
CN201610101521.5A 2013-02-22 2014-02-24 一种dpp-iv抑制剂的中间体 Active CN105669682B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013100565233 2013-02-22
CN201310056523 2013-02-22
CN201410061271.8A CN104003992B (zh) 2013-02-22 2014-02-24 一种抑制dpp-iv的化合物及其中间体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201410061271.8A Division CN104003992B (zh) 2013-02-22 2014-02-24 一种抑制dpp-iv的化合物及其中间体

Publications (2)

Publication Number Publication Date
CN105669682A CN105669682A (zh) 2016-06-15
CN105669682B true CN105669682B (zh) 2019-08-30

Family

ID=51364925

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410061271.8A Active CN104003992B (zh) 2013-02-22 2014-02-24 一种抑制dpp-iv的化合物及其中间体
CN201610101521.5A Active CN105669682B (zh) 2013-02-22 2014-02-24 一种dpp-iv抑制剂的中间体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410061271.8A Active CN104003992B (zh) 2013-02-22 2014-02-24 一种抑制dpp-iv的化合物及其中间体

Country Status (2)

Country Link
CN (2) CN104003992B (fr)
WO (1) WO2014127745A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1861077A (zh) * 2001-07-06 2006-11-15 麦克公司 作为治疗或预防糖尿病的二肽基肽酶抑制剂的β－氨基四氢咪唑并(1,2－A)吡嗪和四氢三唑并(4,3－A)吡嗪
CN1882551A (zh) * 2003-07-31 2006-12-20 麦克公司 用作用于治疗或预防糖尿病的二肽基肽酶－iv酶抑制剂的六氢二氮杂吖庚因酮

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316416T2 (de) * 2002-03-25 2008-06-26 Merck & Co., Inc. Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
US20060052382A1 (en) * 2002-12-20 2006-03-09 Duffy Joseph L 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1861077A (zh) * 2001-07-06 2006-11-15 麦克公司 作为治疗或预防糖尿病的二肽基肽酶抑制剂的β－氨基四氢咪唑并(1,2－A)吡嗪和四氢三唑并(4,3－A)吡嗪
CN1882551A (zh) * 2003-07-31 2006-12-20 麦克公司 用作用于治疗或预防糖尿病的二肽基肽酶－iv酶抑制剂的六氢二氮杂吖庚因酮

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
7-(3-氨基-3-芳基丙酰)-3-三氟甲基-5 , 6 ,7 ,8-四氢[ 1 , 2 , 4]三唑并[4 , 3-α] 哌嗪的合成;戴延凤等;《化学试剂》;20081130;第30卷(第11期);第836-838页

Also Published As

Publication number Publication date
WO2014127745A1 (fr) 2014-08-28
CN105669682A (zh) 2016-06-15
CN104003992B (zh) 2016-09-28
CN104003992A (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
JP5815746B2 (ja) Ｃ型肝炎ウイルス阻害剤
US6812350B2 (en) Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds
KR100869616B1 (ko) 프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도
TW202132328A (zh) 具有Kras抑制作用的環狀胜肽化合物
CN104837830B (zh) 作为cb2受体激动剂的吡嗪衍生物
JP2005533771A (ja) ジペプチジルペプチダーゼｉｖ阻害剤としてのフッ素化環式アミド
CN108778278A (zh) 适用作ssao抑制剂的氨基嘧啶化合物
JP2006508975A (ja) ジペプチジルペプチダーゼｉｖを阻害するフッ素化環状アミド
TWI809334B (zh) ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式
TW200817403A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2006030847A1 (fr) Nouveau derive du pyrazole bicyclique
TW200538101A (en) Dipeptidyl peptidase-Ⅳ inhibitors
AU2005251461A1 (en) 1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase IV (DPP-IV) inhibitors for the treatment of Type 2 diabetes mellitus
TW201402613A (zh) Ｉａｐ拮抗劑
KR101280786B1 (ko) 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물
CN113166149B (zh) 用于治疗ii型糖尿病的化合物
CN101448785B (zh) 二肽基肽酶iv抑制剂、它们的制备方法以及含有它们的药物组合物
JP5661177B2 (ja) ヘキサヒドロピロロ［３，４−ｂ］ピロール誘導体、その製造方法及び用途
CN105669682B (zh) 一种dpp-iv抑制剂的中间体
CN104045625A (zh) 活化ampk 的吲哚类和吲唑类化合物
CN101087757B (zh) 二肽基肽酶ⅳ抑制剂、含有它们的药用组合物及其制备方法
CN110352191A (zh) 吡咯烷酮化合物
CN104016993B (zh) 一种抑制dpp-iv的化合物及其中间体
KR100848490B1 (ko) 베타아미노기를 갖는 1,2,5-트리아제판 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
RU2769715C1 (ru) Агонисты рецептора glp-1 и их применение

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 610000 R&D Building 1001, No. 88 South Keyuan Road, Fengjiawan Industrial Park, Chengdu High-tech Zone, Sichuan Province

Applicant after: Chengdu Pioneer Drug Development Co., Ltd.

Address before: 610041 R&D Building 1001, No. 88 South Keyuan Road, Fengjiawan Industrial Park, Chengdu High-tech Zone, Sichuan Province

Applicant before: Chengdu lead drug development corporation, Ltd.

GR01 Patent grant
GR01 Patent grant